Commerzbank Aktiengesellschaft FI Trims Stake in Humana Inc. (NYSE:HUM)

Commerzbank Aktiengesellschaft FI lowered its position in Humana Inc. (NYSE:HUM) by 26.7% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,105 shares of the insurance provider’s stock after selling 1,863 shares during the period. Commerzbank Aktiengesellschaft FI’s holdings in Humana were worth $1,617,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Global Assets Advisory LLC bought a new stake in shares of Humana in the 1st quarter worth $5,240,000. Gateway Investment Advisers LLC boosted its stake in Humana by 124.6% during the first quarter. Gateway Investment Advisers LLC now owns 2,201 shares of the insurance provider’s stock valued at $763,000 after buying an additional 1,221 shares during the last quarter. Brookstone Capital Management bought a new stake in shares of Humana in the 1st quarter worth about $448,000. Future Financial Wealth Managment LLC purchased a new position in shares of Humana in the 1st quarter worth approximately $173,000. Finally, 180 Wealth Advisors LLC boosted its stake in Humana by 8.1% during the first quarter. 180 Wealth Advisors LLC now owns 1,023 shares of the insurance provider’s stock worth $355,000 after buying an additional 77 shares during the period. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

NYSE HUM opened at $261.62 on Wednesday. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $527.18. The stock has a 50-day moving average of $312.24 and a 200 day moving average of $337.81. The stock has a market capitalization of $31.53 billion, a price-to-earnings ratio of 16.33, a PEG ratio of 1.91 and a beta of 0.50.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The firm had revenue of $29.54 billion for the quarter, compared to analyst estimates of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the firm posted $8.94 EPS. Sell-side analysts anticipate that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Investors of record on Monday, September 30th will be given a dividend of $0.885 per share. The ex-dividend date of this dividend is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.35%. Humana’s dividend payout ratio (DPR) is presently 22.04%.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the stock. Piper Sandler downgraded shares of Humana from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $392.00 to $274.00 in a research note on Thursday, October 3rd. Stephens reaffirmed an “equal weight” rating and set a $250.00 target price on shares of Humana in a research report on Wednesday, October 9th. Deutsche Bank Aktiengesellschaft cut their price target on Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a report on Thursday, October 3rd. Royal Bank of Canada decreased their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating for the company in a research note on Tuesday, October 8th. Finally, Barclays decreased their price target on shares of Humana from $364.00 to $250.00 and set an “equal weight” rating for the company in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, nineteen have issued a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $315.33.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.